🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Europe needs a sustainably funded influenza research and response network - especially in the light of H5N1 and current developments in the US. Read our commentary in The Lancet ID: thelancet.com/journals/lanin… With wendybarclay, Marion Koopmans, publications: https://pure.eur.nl and many other colleagues.

💊Very happy to share our paper in The Lancet Infectious Diseases on doxypep: hopes and fears for implementation . 😍This is a joint effort with @GilmoreJNurse ; Manik Kohli; Eddy - edftmxxx (400k) ; ben; and Laia Ventura 👉Access here: thelancet.com/journals/lanin…

In this editorial in The Lancet Infectious Diseases with Arturo Casadevall , we show how SARS-CoV-2 evolution once again defeated an anti-Spike mAb (#sipavibart / #AZD3152) before it reached the marked. thelancet.com/journals/lanin… Bart Rijnders Shmuel Shoham David J Sullivan emanuele nicastri Thomas hueso

Delighted to share my latest clinical case report published in The Lancet Infectious Diseases from Fudan University, highlighting a case of mistaken identity—sinusitis mimicking meningioma! Thanks to Faden Lab from Mass Eye and Ear Harvard University, the co-first author, for his invaluable guidance

🆕The absence of essential diagnostic & therapeutic tools is a crucial barrier to Zika virus preparedness & response. A The Lancet Infectious Diseases & Lancet Microbe Series outlines a comprehensive strategy to advance research, policy, & investment to address this: hubs.li/Q038m_VF0

Very pleased to share our latest paper in The Lancet Infectious Diseases. This paper considers the complex issues of antimicrobials at the end-of-life, including nonclinical factors that must be navigated in the dying process. Thanks to Billy Rosa, PhD, MBE, APRN for leading this! sciencedirect.com/science/articl…

With cholera resurging in recent years, this letter by GTFCC Secretariat The Lancet Infectious Diseases highlights the crucial principle of adaptive surveillance. It stresses that surveillance must be tailored to different epidemiological contexts, as outlined in their guidance thelancet.com/journals/lanin…

Cholera has skyrocketed globally in recent years, linked to factors such as conflict, displacement, and climate change. A lack of political commitment & investment in controlling cases has also contributed to its resurgence. Read more in the latest news piece from

Out now in The Lancet Infectious Diseases our #SEMVAc study demonstrates that the MVA-BN vaccine (Imvanex/Jynneos) is safe & effective against #mpox, but a single dose does not sufficiently protect people living with #HIV. Thank you EU Medicines Agency for support. thelancet.com/journals/lanin…

RESISTANCE IN TB AND HIV: Article we just wrote for the The Lancet Infectious Diseases on a consequence of HIV global funding cuts that has not been discussed much -the development of drug resistance in HIV and TB thelancet.com/journals/lanin…

Well done to my sister Anja Saso on her excellent RCT just published in The Lancet Infectious Diseases looking at effect of #pertussis vaccine in pregnancy Huge amount of work at MRC Unit The Gambia at LSHTM 🇬🇲 Proud brother! thelancet.com/journals/lanin…

We are hiring a Deputy Editor for The Lancet Regional Health – Southeast Asia Find out more about the role here lnkd.in/gBEyCJKB The Lancet G Kang Soumya Swaminathan World Health Organization South-East Asia Anurag Agrawal SwarupSarkar Vivek Kute Professor Tissa Wijeratne OAM MD PhD lakshmivijaykumar

1/5 🔥 Hot off the press — PAXLC trial results now in The Lancet Infectious Diseases （🇯🇵日本語解説付き） After 3 years of dedicated work, we’re proud to share results from PAX LC: a fully decentralized, double-blind, placebo-controlled, FDA-authorized Phase 2 trial of Paxlovid

We were so happy to partner with participants on this decentralized, technology-enabled trial. Innovative way to do trials. I just wish the result had been better for patients. Prof. Akiko Iwasaki Yale School of Medicine YaleClinicalResearch The Lancet Infectious Diseases medicine.yale.edu/news-article/d…

While little is known about the mysterious #Oropouche virus in Latin America, a number of deaths have been reported along with impacts on unborn babies. A #CharitéBerlin study has discovered that the pathogen is more widespread than previously thought. charite.de/en/service/pre…

Now, there is a 2024 WHO Bacterial Priority Pathogens List 🆕 An article in The Lancet Infectious Diseases details the processes involved in this important revision ⤵️ bit.ly/3EoCZUG

In The Lancet Infectious Diseases, MSF highlighted the urgent need for a ring vaccination strategy to curb the cholera outbreak in DRC and neighbouring countries, worsened by ongoing conflict. #Cholera #GlobalHealth #DRC 💉 shorturl.at/2hRzU

A study in The Lancet Infectious Diseases confirmed the safety & efficacy of single low-dose primaquine in reducing malaria transmission in young children & could support global #malaria elimination efforts & limit the spread of drug resistant #malaria iddo.org/news/new-study… Tropical Medicine Oxford

Trachoma is the leading infectious cause of blindness worldwide. In a new Seminar, Esmael Habtamu & colleagues provide an overview of the key clinical and public health features of trachoma. Explore now ➡️ hubs.li/Q03nWybF0

☀️ On the cover of The Lancet Infectious Diseases June issue in time for European arbovirus season, the PREPARE Europe MERMAIDS-Arbo doublebill of papers with commentary now in print - thank you! 🦟 Full issue: thelancet.com/journals/lanin… 🤒 Clinical outcomes: thelancet.com/journals/lanin… 🦠